Pablo Legorreta is the Chief Executive Officer and Chairman of Royalty Pharma since its founding. He has a strong background in finance and holds an MBA from Columbia Business School. Before starting Royalty Pharma, he worked as an investment banker...

Current Market Cap

$11.76B

Number of Employees

89

Total Compensation

2020 - 2023

Trending down by -65.77% last year
Showing total compensation for the last 2020 - 2023

Stock

Down by -100.00% last year

Salary

Up by 0.00% last year

Bonus

Up by 0.00% last year

Other

Down by -9.24% last year

Year

2023

Total Compensation

$84.84M

Salary

$0.00

Board Justification

The compensation philosophy emphasizes alignment with shareholder interests and long-term performance, with a focus on attracting and retaining top talent through performance-based compensation.

Bonus

$0.00

Board Justification

Mr. Legorreta does not participate in our annual cash bonus plan.

Other

$84.84M

Board Justification

Mr. Legorreta is entitled to certain profits of the Manager, which consist of the management fee from Royalty Pharma less the expenses of the Manager, including operating expenses and the compensation of the employees of the Manager.

Restricted Stock

$0.00(0 Equity Performance Awards)

Board Justification

Mr. Legorreta is entitled to Equity Performance Awards but does not receive employee compensation for his services.

Performance Metrics

The performance metrics for Mr. Legorreta's compensation are tied to the profits of the Manager and the overall performance of Royalty Pharma.

SEC Filing

From April 25, 2024

Pablo Legorreta

Founder and CEO of Royalty Pharma

R

Education

MBA from Columbia Business School

Field of Expertise

Finance & Banking - Finance

Born

April 1, 1963 - 61 years ago

Is Founder?

Yes

Current Tenure

4 years 5 months (Jun 2020 - Present)

Previous Experience

Founder of Royalty Pharma

View Holdings

Insider Holdings of Pablo Legorreta

PROKRPRX

$142.85M

-$237.65M (-62.46%)

Last Insider Trade

PROK

$54.74M

PROK at $2.42/share

Jun 13, 2024

Purchase